KRAS and non-small cell lung carcinoma: In fact, The Cancer Genome Atlas (TCGA) research network showed that the principal driver alterations in NSCLC (i.e., LUAD)—either EGFR mutations or KRAS mutations—include the co‐occurrence of several others, commonly with TP53 mutations, as well as serine/threonine kinase 11 (STK11) and kelch‐like ECH‐associated protein 1 (KEAP1) mutations and alterations [79].